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Mesoporous silica films as a novel biomaterial:
applications in the middle ear†
Nina Ehlert,ab Peter P. Mueller,c Martin Stieve,zd Thomas Lenarzd and
Peter Behrens*ab
In this tutorial review we present the process of the development of functional implants using
mesoporous silica. The diﬀerent steps from chemical synthesis and physicochemical characterization
followed by in vitro testing in cell culture assays to clinically relevant in vivo animal studies are examined.
Since the end of the 1990s, mesoporous silicas have been considered as biomaterials. Numerous
investigations have demonstrated their non-toxic and biocompatible properties. These qualities in
combination with the unique properties of high surface area and pore volume, uniform and tunable pore
sizes and chemical modifiability are the reasons for the great scientific interest in this field. Here we show
that besides bulk materials or mesoporous silica nanoparticles, mesoporous silica films are highly
promising as coatings on medical prostheses or implants. We report on the development of
functionalized mesoporous silica materials specifically for middle ear applications. Middle ear prostheses
are used to restore the sound transmission through this air-filled cavity when the small bones of the
middle air (the ossicular chain) have been destroyed by disease or by accidents. In addition to optimal
restoration of sound transmission, this technique bears several challenges, e.g. an ongoing bacterial
infection or the displacement of the prosthesis due to insuﬃcient fixation. To improve the healing
process, a mesoporous silica coating was established on ceramic middle ear prostheses, which then served
as a base for further functionalizations. For example, the bone growth factor BMP2 was locally attached
to the coating in order to improve the fixation of the prosthesis by forming a bony connection to the
remainder of the ear bones. Further, an implant-based local drug delivery system for the antibiotic
ciprofloxacin was developed with the aim of fighting bacterial infections. Further possibilities using
mesoporous silica nanoparticles as part of a composite on an implant are briefly discussed.
Key learning points
The way from clinical problems to improved implant materials: materials development, in vitro and in vivo testing.
Establishment of mesoporous thin silica films on ceramic surfaces.
Degradation of mesoporous silica films in physiological medium.
Implant-carried mesoporous silica films as drug delivery systems.
Implant-based delivery of biomolecules using mesoporous silica coatings.
Introduction
Since the discovery of mesoporous materials in the early
1990s,1–3 the family of mesoporous silica materials has aroused
great interest which is still growing rapidly. These materials are
created by condensation of amorphous silica around ordered
aggregates of amphiphilic molecules, also designated as
structure-directing agents (SDAs). These molecules are then
removed by a calcination or extraction step leading to a porous
network.4 This synthesis strategy can yield pore sizes from 2 to
10 nm with various pore topologies like cubic or hexagonal
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in 2D or 3D.5 The most important properties of these materials
are their high surface areas and pore volumes, the tunable and
uniform pore size, and the convenience with which chemical
modifications can be carried out due to the presence of surface
silanol groups.6
These properties have been evaluated for a range of applica-
tions which are typical for porous materials. A novel application
area for which mesoporous materials have been studied from the
beginning of the 2000s is the area of biomaterials. Mesoporous
silicas meet the basic requirements for biomaterials, as they are
non-toxic and have a high biocompatibility.7 In addition to many
studies certifying these favourable properties, only a few exam-
ples for harmful reactions have been found in vivo.8,9 Normal
synthetic procedures for mesoporous silicas deliver a powder of
aggregated particles which is diﬃcult to apply in biomedical
devices.10 An alternative which is pursued by many scientists is
the use of mesoporous or nanoporous silica nanoparticles.6,11–13
As an example of the progress in this field, the FDA has recently
approved the first in human trial of silica nanoparticles.14 An
alternative application form are coatings of mesoporous silica,
which can be applied directly with a pre-formed implant or
prosthesis. Thin films of mesoporous silica can be produced on
various substrates using dip- or spin-coating procedures.15,16
Their formation proceeds via the EISA (Evaporation-Induced
Self-Assembly) process.17 Applying this process in the dip-coating
method, a substrate is immersed into a diluted synthesis
solution. At the moment of extraction, the concentrations of
the components increase and they form larger ordered aggregates
(micelles from the amphiphilic SDAs) or undergo condensation
(the silica precursors) due to the evaporation of the solvent at the
border between liquid and air. Alternatively, spin-coating can be
used. Considering the possibility to directly equip implants with
the favourable properties of mesoporous silica, we have focused
on establishing coatings of this material on known implant
materials, on using the possible functions of such coatings and
on testing them in cell culture and animal experiments.
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As a test field for this work we have chosen the middle ear.
The middle ear is an air-filled cavity; it is separated from the
outer ear by the ear drum (tympanic membrane) and from the
inner ear by the oval window. Its main task is to transduct
the air waves reaching the drum (which correspond to sound)
to liquid waves in the cochlea in the inner ear, where the
pressure fluctuations are further processed by hair and nerve
cells and then sent as electrical signals to the brain. For this
task, the middle ear is equipped with a mechanical transduc-
tion system consisting of three small bones, the malleus, the
incus and the stapes (Fig. 1a). The malleus is directly attached
to the drum and the stapes is fixed on the membrane of the oval
window. This ossicular chain also provides a small amplifica-
tion eﬀect due to the leverage action of the bones. The flexible
joints between the three bones can compensate changes in the
atmospheric pressure and can reduce sound transmission in
response to loud sounds to protect the inner ear.
As a consequence of diseases of the middle ear, the middle
ear bones can be destroyed. Typical pathological manifestations
are chronic bacterial infections or cholesteatoma, tumour-like
aggregations of epidermal and connective tissues within the
middle ear which do not belong there. The destruction of the
middle ear bones constituting the ossicular chain disrupts
sound transmission and consequently leads to hearing loss in
the aﬀected ear. Hearing can be restored using a prosthesis, the
so-called total ossicular replacement prosthesis (TORP), which
re-establishes the contact between the drum and the oval
window, on which typically a residue of the stapes plate has
remained undestroyed (Fig. 1b). As for any implant, the basic
requirement for the prosthesis material is of course a good
biocompatibility. In this special case, optimal sound transmis-
sion capabilities are also important. This is usually achieved
using stiﬀ materials such as metals, ceramics, composite
ceramics or strong polymers.18 Diﬀerent prostheses made of
such materials are commercially available and are chosen
following the conviction of the particular surgeon, usually
giving satisfying hearing results.
Although available middle ear prostheses are implanted
frequently, there are still problems to solve in order to improve
the quality of life for the patients.19 Often, a revision surgery,
which is of course straining for the patient, becomes necessary
due to displacement of the prosthesis. When implanted the
prosthesis is simply inserted between the eardrum and the
residual stapes bone footplate with no additional fixation.
In certain cases, the prosthesis may become dislocated.
Another problem is that the construction of the middle ear
prosthesis is inflexible. Due to the joints between the ossicular
bones, the ossicular chain can deform, thus mediating pressure
variations. This task cannot be accomplished by a stiﬀ TORP.
Therefore, a soft collagen pad (taken from another part of the
body of the patient) is usually placed between the tympanic
membrane and the head part of the prosthesis. Another crucial
problem in middle ear surgery is infection, which can be
brought to the implantation site during the operation, but is
more often due to the persistence of the chronic infection
which had originally caused the degradation of the middle
ear bones.20 Finally, when the destruction of the middle ear
bones had been caused by a cholesteatoma, a relapse may occur
after its surgical removal.
As satisfying hearing results can be obtained using pros-
theses made from stiﬀ standard biomaterials, we have focused
on developing measures against the above-mentioned healing
disorders. For this purpose, we have chosen prostheses made
from Bioverits II. This is an advanced glass–mica ceramic
implant material which is highly biocompatible, insoluble and
Fig. 1 (a) Anatomic situation in the middle ear with the ossicular chain consisting of three small bones, malleus, incus and stapes (or hammer, anvil, and stirrup);
(b) replacement of the destroyed ossicular chain by a middle ear prosthesis; (c) middle ear prosthesis made of the glass–mica ceramic Bioverits II, as used for animal
experiments in rabbits (for humans the total length is ca. 8 mm); (d) specific functionalizations of a middle ear prosthesis with a mesoporous silica coating, which is
used for a site-specific attachment of a growth factor and for local drug delivery.
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corrosion resistant. Furthermore, Bioverits II is clinically well-
established, mainly as a bone replacement material in skull
and middle ear reconstructive surgery.21–25 A typical middle ear
prosthesis made from this material is shown in Fig. 1c.
Our approach is based on coating Bioverits II middle ear
prostheses with a mesoporous silica layer which is then locally
functionalized according to the diﬀerent requirements
(Fig. 1d). The idea to improve the fixation of the prosthesis
relies on improving the connection between the prosthesis and
the oval window by inducing the growth of new bone starting
from the stapes footplate residue which is typically present on
the membrane separating the middle from the inner ear. The
formation of new bone can be induced by the bone growth
factor BMP2 (Bone Morphogenetic Protein 2) which we attach
selectively at the tip of the prosthesis pointing to the inner ear.
For this purpose, we use the mesoporous silica film with its
high surface area and reactive silanol groups.
Middle ear infections continuing after the implantation or
triggered by the surgery are combated using antibiotics.
Usually, these are applied systemically which is stressful for
the body and can cause harmful side eﬀects. Additionally, such
a systemic treatment of the infection may be insuﬃcient when
the bacteria can form a treatment-resistant biofilm on the
implant surface.26 Therefore, it would be a great advantage
to immediately fight the bacteria eﬀectively before biofilm
formation can take place, and thereby permit an undisturbed
healing process. For this purpose, we used the pore system
of the mesoporous silica coating as a reservoir for an anti-
biotic (Fig. 1d). In this way, the implant itself directly and
locally delivers the drug. This strategy has the advantage to
avoid possible side eﬀects caused by a systemic administra-
tion of the drug, where much higher doses would aﬀect the
whole body.
In the following, we describe the preparation of mesoporous
silica layers on glass slides (as a model system) and on
Bioverits II and their physico-chemical characterization.27
Importantly, the stability of the coatings in a physiological
medium is investigated and their biocompatibility is studied
using cell cultures and animal experiments.27–32 We then show
how to immobilize the bone growth factor BMP2 onto
the mesoporous coating,31,33,34 focusing on methods how to
quantify the amount of this protein bound.33 For the reliable
attachment of BMP2, the mesoporous silica has to be modified,
and this is also the case in the construction of an eﬃcient drug
delivery system for an antibiotic. The development of this
system and especially its comprehensive testing using in vitro
cell and bacteria culture studies32 as well as animal experi-
ments will be described.31 Finally, possible further improve-
ments of middle ear prostheses are discussed, for example with
regard to prevent the relapse of a cholesteatoma. Throughout
this tutorial review, we will try to make clear how the inter-
disciplinary interaction between material chemists, biologists
and clinicians on the path from chemical synthesis and
physicochemical characterization to in vitro testing as well as
biological and functional evaluation in vivo can lead to novel
interesting biomaterials.
Mesoporous silica films on implant surfaces
The preparation of mesoporous silica films has been investi-
gated thoroughly on a variety of smooth substrates and has been
shown to proceed according to the EISA process.17 For preli-
minary investigations, we have used glass slides as substrates,
as Bioverits II, an approved biomaterial, is rather expensive.
The results obtained on glass slides were then transferred
to this glass–mica ceramic, considering especially its much
rougher surface.
For the generation of the mesoporous silica coatings,
a standard reaction mixture consisting of tetraethoxysilane,
ethanol, water, hydrochloric acid and an SDA similar to
Pluronics 123 was used.27,32,33,35 The substrates were dip-
coated, dried at high air humidity and at 60 1C, followed by a
final calcination step at 415 1C. Because of the rough surface
properties of the ceramic substrates, it was necessary to pro-
duce three layers of the film in order to achieve a total coverage
of the surface.
X-ray diﬀraction (XRD) patterns show rather broad reflec-
tions at 1.11 2y for the mesostructured films which shifts to
1.61 2y for the calcined ones (Fig. 2), reflecting regular struc-
tures of 8.0 nm and 5.5 nm repeat size, respectively. As no
higher-order reflections are present, but only one very broad
additional peak at ca. 31 2y, the pores in this coating have no
ordered arrangement, as a hexagonal, cubic or lamellar packing,
and no long-range preferred orientation with regard to the
substrate, as previously described.32,33,35 Correspondingly, the
pore topology in these coatings is disordered, similar to bulk
mesoporous materials of the LMU-136 or KIT-137 type. The fact
that the same reflections can be found on the coated glass
slides as well as on the coated Bioverits II samples shows that
the porous structure of the silica film is present on the ceramic
substrate, too. The Bioverits II samples present another reflec-
tion at 91 2y in the investigated 2y range; this is caused by the
crystalline parts of the glass–mica material.27
Fig. 2 X-ray diﬀraction patterns of silica coatings on Bioverits II substrates (top
two lines) and on glass slides (bottom two lines). ‘‘ms’’: as-synthesized mesos-
tructured coatings still containing the amphiphilic SDA; ‘‘mp’’: mesoporous
coatings after removal of the SDA. Adapted with permission from ref. 27.
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In accordance with the XRD results, electron microscopic
investigations reveal a disordered arrangement of nanopores
within the silica film. In Fig. 3 images of silica films on glass
are presented. With low resolution, the scanning electron
microscope (SEM) image in Fig. 3a shows a side-view of an
intentionally broken layer, where the direct attachment of the
film on the glass substrate can be observed. Whereas at this
magnification the coating appears smooth, a closer look onto
the surface (Fig. 3b) reveals pore mouths on the surface from
which the pore system can be accessed. The pore mouths,
however, do not form a regular pattern. The disorder in the
pore system is clearly revealed in Fig. 3c, which shows a
scanning transmission electron microscope (STEM) high reso-
lution image of a cross section of a mesoporous silica film.
The channels run primarily parallel to the substrate, but do
so in all directions. These results are in good agreement
with the presented XRD results.27 The thickness of the film
can be determined as ca. 40 nm. Further investigations showed
that the layer thickness for one silica film lies between 30
and 150 nm.32
In order to use mesoporous silica layers as a surface
modification on implants, we transferred the synthesis proce-
dure to the ceramic implant material Bioverits II as a substrate.
In contrast to glass substrates, this material has a rather rough
surface structure. In order to safely fill the surface cavities and
potholes of the Bioverits II surface, the coating procedure was
performed three times in total. The procedure was successful as
can be seen in Fig. 4, and by a STEM cross section of the
mesoporous silica film on Bioverits II (Fig. 5). Mesoporous
silica material can be detected in the cavities of the rough
surface of the glass-ceramic. Similar to the coatings on glass
slides, an irregular system of mesopores can be observed.27 An
orientation of the channels parallel to the substrate can only be
observed very close to the surface of the support (Fig. 5b,
arrows). The lower orientational order as compared to the
findings with glass slides as substrates (see Fig. 3c) is probably
due to the more irregular liquid flow during dip-coating on
rough Bioverits II substrates as compared to the smooth glass
surfaces. Furthermore, SEM investigations showed that the
adhesion of the mesoporous silica film was good on glass
substrates as well as on Bioverits II.
Furthermore, krypton sorption experiments revealed a
surface area of about 11.2 cm2 cm2 of the macroscopic
substrate.32
Stability tests
It is well-known that thin films of mesoporous silica are not
stable in water and in biological media.38 In order to investigate
the stability of our coatings, we exposed films prepared on glass
slides in a typical cell culture medium (10% v/v fetal calf serum
in 0.01 M phosphate-buﬀered saline solution) at 37 1C for
diﬀerent time intervals. After this treatment, the presence of
the mesoporous structure was checked by XRD measurements
as presented elsewhere.33 After having determined the point of
Fig. 3 Electron microscopic characterization of a mesoporous silica layer on a
glass slide. (a) Low-resolution SEM image corresponding to an inclined sight on
an intentionally broken layer; (b) SEM top view onto the surface of the film
showing open pore mouths; (c) STEM image of a cross section of the film
revealing the pore topology. Adapted with permission from ref. 27.
Fig. 4 SEM pictures of a (left) rough surface of native Bioverits II, and (right) of a smooth surface covered with a mesostructured silica coating.
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time where the XRD-visible mesostructure collapses, further
investigations on such samples were performed by FE-TEM and
STEM in order to clarify the rearrangement of the film structure.
XRD patterns measured on the films after diﬀerent exposure
times revealed that the mesoporous structure of the film is
destroyed, showing diﬀerent successive phases discussed in
detail elsewhere.33 The intensities of the reflections at 1.61 2y
and at 3.01 2y decreased within the first six hours of exposure,
continuing up to an exposure time of twelve hours. Afterwards
the reflection at 3.01 2y is no longer present, but a broad
reflection in the range of 2.0 to 2.51 2y can be seen (Fig. 6).
After longer periods of time, no diﬀraction peaks appear anymore.
These changes in the XRD patterns are indicative of diﬀerent
states passed through during a structural rearrangement of
the silica layer. The disordered pore structure of the original
coating collapses and a material with a lower degree of ordering
is formed. Finally also this lower-order phase is not detectable
anymore in the XRD pattern.27
Interestingly, further investigations on glass substrates
showed that a silica film with reduced thickness is still present
on the surface for at least 24 hours. When the mesoporous
silica film is somehow protected, for example by silanization or
the attachment of a protein,35 reflections from the nanoporous
structure can be observed for longer time periods.27
We were interested in the structure of the intermediate phase
with the characteristic broad peak in the range of 2.0 to 2.51 2y
and performed a corresponding sample high-resolution FE-TEM/
STEM analysis. Fig. 7 shows corresponding images. The pictures
can be interpreted in terms of transformation of the mesoporous
silica layer to a packing of silica nanoparticles with a size of about
7–8 nm. Their packing appears to be partly ordered, as can be
seen from the striations visible in the pictures in Fig. 7. The
transformation process probably involves the destruction of the
original pore network, e.g. by Ostwald ripening-type processes,
and a rearrangement of the silica material.27
Biocompatibility tests
The initial test for biocompatibility normally consists of cell
culture experiments. Although such in vitro tests have only
limited significance for the situation in living beings, they
can detect toxicity and may help to reduce the number of
animal experiments. General biocompatibility tests are usually
performed with well-defined standard cell lines such as fibro-
blasts, HeLa or hepatoma cells. For specific applications, the
informative value can be increased by using more specialized
cells, e.g. primary human cells, Schwann cells for nerve regenera-
tion or osteoblasts for bone reparation. Also stem or precursor
cell lines can be used, for example pluripotent mesenchymal
stem cells, which can under appropriate conditions be diﬀeren-
tiated to osteoblasts.
In the case of our mesoporous silica coatings, samples for
cell culture tests can be easily prepared on circular glass slides
with diameters corresponding to the size of the containers
Fig. 5 STEM images of a cross section of a mesoporous silica coating on Bioverits II substrates at lower (a) and higher magnification (b), showing the disordered
mesoporous structure of the coating. Arrows point to orientationally ordered pore channels close to the substrate surface.
Fig. 6 X-ray diﬀraction patterns of a mesoporous silica layer on glass. Samples
were exposed to a typical mammalian cell-compatible medium (10% v/v fetal
calf serum in 0.01 M phosphate-buﬀered saline solution) for diﬀerent times.
Reprinted with permission from ref. 33.
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wherein these tests are usually performed, the so-called wells
(typically 10 or 13 mm). Initial tests of the biocompatibility of our
silica were performed with the murine fibroblast cell line NIH3T3
and with the epithel-derived cell line HEK293. Both showed
excellent biocompatibility of the coating. Here we show our
results obtained with a cell type representative of bone tissue–
implant interactions, namely the murine mesenchymal precursor
cell line C3H10T1/2. Diﬀerent mesoporous silica variants pre-
pared with diﬀerent amphiphilic block copolymers and diﬀering
pore sizes were tested. For comparison, bare standard glass slides
and glass slides coated with an unstructured silica layer were also
tested. The unstructured silica layer was prepared in a similar
way to the mesoporous coating, but without using a surfactant.
Cells were seeded onto the samples and the interactions were
monitored microscopically. During the initial 3 to 5 hours of the
cell culture experiment, cell attachment takes place; to exclude
any interference by proteins adhering to the surfaces, serum was
omitted from the cell culture medium during this phase. The
cells adhered well to unstructured as well as to nanoporous silica
layers and also to glass. During the subsequent incubation phase
under standard cell culture conditions, the cells spread out on
the coated slides. Similar to the attachment phase, no diﬀerences
were observed in the cell response for the diﬀerent materials; also
diﬀerent pore sizes of the mesoporous silicas did not influence
the behavior of the cells. Cell proliferation on these materials was
almost as high as on the cell culture-optimized polystyrene
surface. The results of cell culture tests can for example be
quantified by (automatically) counting the cells (Fig. 8).
Whereas glass slides are a convenient substrate for the
deposition of mesoporous silica for cell culture testing, further
development of these coatings for implant applications
requires a substrate which has been established as a biomaterial
and which is used for the construction of prosthesis. We have
chosen Bioverits II, a glass–mica ceramic, for this purpose due
to the chemical compatibility of the silicate systems. Bioverits II
is a commercially available implant material which is highly
bioactive especially for bone-forming cells which is used for a
variety of medicinal applications, for example as bone replace-
ment for temporal or skull bones or as middle ear prostheses.39
Especially the middle ear is a convenient location for carrying
out animal studies which poses only limited strain for the
animals and oﬀers a control at hand, namely the other ear
which is usually left untreated.40–42
The combination of a mesoporous silica layer on a Bioverits
II again has to be tested for biocompatibility. Corresponding
cell culture tests showed that the surface covered with nano-
porous silica is somewhat less bioactive than the plain
uncoated, highly ‘‘bone-friendly’’ Bioverit material. In Fig. 9 it can
be seen that the cells on uncoated Bioverits II have spread out,
Fig. 7 FE-TEM (a) and STEM (b) images of a cross-section of a mesoporous silica film exposed for 12 h to a typical cell culture medium (10% v/v fetal calf serum in
0.01 M phosphate-buﬀered saline solution). After exposure to the medium, the mesoporous structure of the silica film rearranges to a partly ordered packing of
spherical silica nanoparticles with a size of seven to eight nanometers. Adapted with permission from ref. 27.
Fig. 8 Results from cell culture tests. Mesoporous coatings with diﬀerent pore
sizes support cell proliferation as well as an unstructured silica coating and as plain
glass, and nearly as well as polystyrene used for cell culture containers. The d values
indicated in nm in the figure were calculated from the most intense reflection in
the XRD patterns of the mesoporous silica coatings. Murine mesenchymal pre-
cursor cells (C3H10T1/2) were seeded on the corresponding substrate and were
incubated with a standard cell culture medium (Dulbecco’s Modified Eagle’s
Medium, DMEM) with 10% fetal calf serum (FCS) for four days at 37 1C in a
humidified atmosphere containing 5% CO2. Adapted with permission from ref. 27.
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whereas on the coated samples the cells are more roundish,
indicating that cellular adhesion is somewhat less favoured.27
After successful in vitro cell culture tests, in vivo animal
studies are the next step in the examination of biocompatibil-
ity. In addition to the biocompatibility, specific reactions of the
surrounding tissue can be studied and also a functional evalua-
tion can be performed. We tested the mesoporous silica film in
the middle ear of rabbits, comparing plain Bioverits II middle
ear prostheses with ones which were covered by a mesoporous
silica layer. The general results confirmed the high biocompati-
bility of the mesoporous silica. Histological studies were per-
formed in order to define the type of tissue which had formed
on the prosthesis. A tendency was found that on coated prosthesis,
somewhat less new bone (Fig. 10a and b) was formed, in agree-
ment with the reduced bioactivity of such samples observed in cell
cultures. Instead, a thin cell layer of mucosa had formed directly
around the prosthesis (Fig. 10c and d).28 The formation of a thin
mucosa corresponds to an excellent biological situation and there-
fore a good implant healing.
Mesoporous silica films as a base for
attachment of biomolecules
As detailed in the Introduction, one of the major problems in
middle ear surgery is the displacement of the prosthesis which is
simply inserted between the tympanic membrane and the oval
window. Our idea to improve the anchoring of the prosthesis is
based on establishing a bony connection between the prosthesis
and the stapes footplate (a bone residue which typically remains on
the oval window membrane after the destruction of the ossicular
chain). The formation of new bone can be induced by the bone
growth factor BMP2 (Bone Morphogenetic Protein 2). When BMP2
is attached selectively at the tip of the prosthesis, bone formation
may occur locally at this spot without a full bony enveloping of the
prosthesis which would impede sound transmission.
In order to develop a procedure for binding BMP2 to
mesoporous silica, we initially worked with the cheaper protein
alkaline phosphatase (ALP), the activity of which can easily be
determined by a colorimetric enzyme assay.35 Results of this
initial study – mainly the use of an aminosilane linker to bind
the protein to the surface – were then transferred to the much
more expensive growth factor BMP2.33 As substrates we used
glass or Bioverits II. For comparison, we also tested the
immobilization capability of a plain substrate surface and of
an unstructured silica layer; the latter was prepared in a similar
fashion to the mesoporous film, but by omitting the amphi-
philic structure-directing agent. For both types of substrates, all
three samples – the plain substrates, the unstructured and the
mesoporous silica coatings – were studied with and without the
linker. Fig. 11 shows the construction of the diﬀerent samples.
The quantification of small amounts of protein attached to a
surface is a delicate task, especially when the specific activity of
the immobilized BMP2 is to be evaluated, for the immobiliza-
tion procedure may reduce part of this activity. This can for
example happen due to conformational changes of the protein
upon attachment to the surface. Also, a growth factor like BMP2
does not act by catalyzing an easily detectable chemical reac-
tion (as an enzyme does), but it acts by binding to a receptor
protein on the outer cell membrane and thereby induces a
specific signaling pathway within living cells bearing this
specific receptor. If an attached BMP2 molecule is misfolded
or sterically hindered, the activity is impeded. However, when
one makes use of this interaction, a highly specific determina-
tion of the amount of active protein can usually be attained.
This can be done for example using a so-called ELISA (enzyme-
linked immunosorbent assay). Here, an epitope of the protein
is recognized by a primary antibody which carries another
antibody which again is linked to an enzyme. This enzyme
catalyzes a reaction which yields a product which is easily
detectable, for example colorimetrically (Fig. 12). In this way,
the amount of BMP2 can be determined which – after binding
to the substrate – still shows the correct epitope to the antibody,
Fig. 9 Results of cell culture tests, comparing uncoated Bioverits II (left) with
Bioverits II coated with a mesoporous silica layer (right). Recombinant murine
mesenchymal precursor cells marked with green fluorescent protein were incu-
bated in a cell culture medium for 3 days. Adapted with permission from ref. 27.
Fig. 10 Results from animal experiments in the middle ear of rabbits. (a) Bioverits II
prosthesis (p) coated with mesoporous silica (the coating is not observable at this
resolution): minor ossification (the formation of new bone) has taken place at the
tip of the prosthesis. (b) On an uncoated Bioverits II prosthesis the ossification is
slightly increased (arrow). (c and d) On other parts of the prosthesis, mucosa has
formed directly on the implant material. On a prosthesis coated with mesoporous
silica a complete and regular mucosa (arrow) layer is present (c), whereas the
mucosal coverage is partly incomplete on uncoated Bioverits II (d). Reprinted
with permission from ref. 28.
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i.e. the amount of BMP2 which is immunologically active. The
ELISA, however, cannot determine whether this BMP2 can still
fulfill its normal biological function. In order to perform such a
more stringent determination, a reporter cell line was con-
structed (Fig. 12) which is used in a special assay, the so-called
BRE-luc test (BRE: BMP2-responsive element; luc: luciferase).43,44
When BMP2 binds to the cognate receptor of these cells, a signal
pathway is activated which ends in the nucleus of the cell.
In unmodified cells this would lead to the expression of genes
typical of bone-forming cells (osteoblasts). In the genetically
altered cells, the gene for the production of luciferase is activated
instead. Luciferase is an oxidative enzyme which shows biolu-
minescence. The intensity of the resulting bioluminescence is
then proportional to the amount of biologically active BMP2.
The results of the BMP2 quantification studies are presented in
Fig. 13. For the samples based on glass substrates, both quantifica-
tion methods showed that it was possible to attach small amounts
of BMP2 on the glass substrates and diﬀerent silica coatings when
the aminosilane linker was used. According to the ELISA test, a
native glass surface modified with the aminosilane linker bound
about 5 ng cm2 BMP2 (the area refers to the macroscopic surface
of the samples). These values increased to about 13 to 15 ng cm2
BMP2 when the unstructured or the mesoporous silica coating was
applied. The cell-based BRE-luc assay detected considerably smaller
amounts of biologically active BMP2: about 2 ng cm2 for the
amino-modified unstructured and 5 ng cm2 for the amino-
modified mesoporous coating. With this method, no BMP2 could
be detected on the uncoated but amino-modified glass surface.
With bothmethods, no BMP2 was observed for all types of surfaces
when no amino modification was applied.
On Bioverits II substrates, considerably higher amounts of
immobilized BMP2 could be achieved as compared to the glass
surfaces. The BRE-luc test detected about 67 ng cm2 for the
amino-modified unstructured and more than 100 ng cm2 for
the amino-modified mesoporous surface. To validate the latter
result, the experiment was repeated twice for the mesoporous
surface; in both cases even higher amounts of 156 and
160 ng cm2 bound BMP2 were detected. All tests carried out
for comparison (omitting the silane or a silica coating or both)
gave values below 4 ng cm2 BMP2. In contrast, the ELISA test
was not able to detect any BMP2, except for the uncoated
amino-modified surface where an amount of 24 ng cm2 was
observed. Obviously, this test is disturbed by the presence of
Bioverits II due to unknown reasons.
In similar experiments, but using an epoxy-bearing silane
instead of the aminosilane as a linker, conflicting results were
obtained. Whereas in the BRE-luc test, the amount of BMP2 was
below the detection limit ofo1 ng cm2 in all cases, the ELISA
detected 58 ng cm2 in the case of an unstructured silica coating
and 46 ng cm2 in the case of the mesoporous silica coating,
when these were epoxy-modified. We were able to reveal by
further experiments that this discrepancy is possibly caused by
a direct binding of antibody molecules to the epoxy functions of
the silanized surface, although these should have been blocked
by a previous treatment with fetal calf serum. This shows that
results from biochemical methods which were originally developed
for solutions or for simple surfaces must be treated with care when
thesemethods are transferred tomore complicated systems. Due to
the low biological activity detected by the cellular test system, the
use of the epoxy modification was abandoned.
Fig. 11 Scheme for the construction of the diﬀerent samples studied for the attachment of BMP2. The substrate is either glass or Bioverits II. Reprinted with
permission from ref. 33.
Chem Soc Rev Tutorial Review
Pu
bl
ish
ed
 o
n 
25
 M
ar
ch
 2
01
3.
 D
ow
nl
oa
de
d 
by
 T
ec
hn
isc
he
 In
fo
rm
at
io
ns
bi
bl
io
th
ek
 (T
IB
) o
n 2
6/1
0/2
01
7 0
9:1
9:3
2. 
View Article Online
3856 Chem. Soc. Rev., 2013, 42, 3847--3861 This journal is c The Royal Society of Chemistry 2013
First in vivo tests of the construct Bioverits II – mesoporous
silica coating – aminosilane – BMP2 have shown that a local
biological action of BMP2 can be achieved. These preliminary
experiments were carried out with corresponding implants which
were placed subcutaneously (below the skin). These cylindrical
Bioverits II implants were fully covered with a mesoporous silica
layer, but only half of this coating was exposed to the aminosilane
and thus able to bind BMP2. The biological reactions on these
two halves of the implant were very distinct,34 as schematically
shown in Fig. 14. For further in vivo studies in the middle ear, the
same procedure for a selective detachment of BMP2 to the tip of
the prosthesis by immersing only this end into the solution
containing the linker 3-aminopropylsilane is possible.
Establishing a mesoporous silica-based drug
release system on implant surfaces
Another clinical problem in the healing of middle ear prostheses
is bacterial infections. Pseudomonas aeruginosa (P. aeruginosa) is
a bacterium which causes middle ear infections and which is
able to form a biofilm on an implant surface. Following a
stepwise strategy, we have developed several variants of a drug
release system based on the pore system of the mesoporous
silica film (Fig. 15).32 We used the antibiotic ciprofloxacin (CFX)
as a drug, which is active against P. aeruginosa and which is also
normally applied to treat infections systemically.
Release curves for these diﬀerent materials A to E were
determined spectrophotometrically (based on the UV absorp-
tion of ciprofloxacin) in the supernatant of a phosphate-
buﬀered saline (PBS) release medium; released amounts are
given in Fig. 16 in mg cm2, referring to the macroscopic surface
of the sample. Using the CFX-loaded bare mesoporous silica
film (corresponding to sample A + CFX in Fig. 16), a fast
discharge, a so-called burst release, was observed, with a rather
small total amount of CFX released. In order to enhance the
amount of the released antibiotic, the mesoporous silica film
was modified by establishing negatively charged sulfonate
groups on the surface.45 Ciprofloxacin molecules carry amino
Fig. 12 Scheme explaining the methods for the quantification of surface-
attached BMP2. The ELISA (top) determines the amount of immunologically
active BMP2, whereas the cell-based BRE-luc test (bottom) recognizes biologically
active BMP2.
Fig. 13 Quantification of BMP2 detected on diﬀerent supports based on glass
(top) and on Bioverits II (bottom) substrates. Native surfaces as well as substrates
with an unstructured and with a mesoporous silica coating were employed,
either in an unmodified form or with a modification derived from 3-amino-
propylsilane. Results from ELISA and BRE-luc tests are given (*: no detectable
amount of BMP-2 after comparison with the blank value; note the diﬀerent scales
of the ordinates). Reprinted with permission from ref. 33.
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groups which can be protonated, lending a positive charge to
them when acidic conditions (pH = 4) are used during the
insertion process, thus supporting uptake. With glass slides as
a substrate, this modification (sample C in Fig. 15) increased
the amount of ciprofloxacin released eightfold. However, in
spite of the electrostatic attraction, the samples still show a
burst release behavior.32
In some cases, a slower and more continuous release of the
drug could be preferable. Therefore, we tested diﬀerent further
modifications in order to establish diﬀerent release rates for
the antibiotic. These modifying reactions were performed on
sulfonated mesoporous silica coatings already loaded with CFX,
so that the chemical processing had to be adapted in such a way
that no premature release of the antibiotic occurred. Therefore,
we used a fast dip-coating process to establish a polymeric layer
of bis(trimethoxysilyl)hexane on top of the drug-loaded silica
film (sample D).46 The use of a bis(trimethoxysilyl)-functionalized
alkane also supplied additional silanol groups, which could
then be used to add a further barrier eﬀect by hydrophobizing
the surface with tetramethyldioctyldisilazane, a reaction which
could be carried out via the vapour phase.47 These two treat-
ments were able to considerably slow down the release (Fig. 16,
glass substrates, samples D and E). With sample E, equipped
with a polymeric barrier derived bis(trimethoxysilyl)hexane and
a hydrophobizing layer prepared with tetramethyldioctyl-
disilazane, a prolonged delivery could be established: after an
only small initial burst, a constant release rate was observed for
more than 30 days, followed by regular smaller doses up to
63 days. The surface coatings did not influence the total
amount of drug released, which in all cases was about
2 mg cm–2 of ciprofloxacin. This fact demonstrates that only
very small amounts of ciprofloxacin were lost during the
additional functionalization steps.
Interestingly, even the native Bioverits II surface demon-
strated a rather high drug release amount of 4.5 mg cm2,
revealing a high drug storage capacity of the plain glass
ceramic. Only a slight increase up to 5 mg cm2 was achieved
here by the mesoporous coating. As with glass-based samples,
the eﬀect of the sulfonic acid modification is pronounced. The
total amount released was raised nearly twofold up to 9 mg cm2.
Again, the novel materials had to be tested for their bio-
compatibility. Fig. 17 shows relative cell densities determined
on cell cultures of NIH3T3 fibroblast cells. Whereas the
sulfonate-modified mesoporous silica shows excellent bio-
compatibility, also when loaded with ciprofloxacin, this prop-
erty is somewhat compromised in the case of those samples
(D and E) which had been additionally coated using silanization
reactions to prolong the release period. Here, cell density is
reduced to about half the value observed for cell culture plastic.32
These additional coatings probably reduce cell adhesion and
proliferation on their surfaces, without necessarily being toxic.
A functional test of antibiotic-loaded samples can also be
carried out in vitro, namely in bacterial cultures. For this test a
special stem of P. aeruginosa was used (PAO1 CTX::lux). Bacteria
of this stem exhibit luminescence as long as they are
alive. Fig. 18 shows the results obtained from experiments
using these bacteria. After 6 h in LB medium (Luria Broth48),
ciprofloxacin-loaded samples showed only about one-eighth of
the bacterial luminescence in comparison to the values obtained
with the mesoporous silica only, with the sulfonate-modified
mesoporous silica and with a glass control. These results show
that the amount of ciprofloxacin of the delivery system is in
principle appropriate to locally curb bacterial proliferation.
Driven by these positive results, animal experiments were
carried out, again in the middle ear of rabbits.49 These posed
special problems, because the middle ear of a rabbit does not
normally show an infection, so that this disease had to be
provoked by inoculating a suspension of P. aeruginosa bacteria
into the middle ear to induce a middle ear infection. The
infected ears were then supplied with Bioverits II prostheses,
which carried a sulfonate-modified mesoporous silica coating.
For the study group, the implants were loaded with ciprofloxacin
(corresponding to sample C as described above); the antibiotic
was omitted in the control group. As typical in animal experi-
ments, the size of the two groups, seven animals each, had to be
kept small. Nevertheless, meaningful results could be obtained,
by monitoring and evaluating various aspects of the clinical
status and the behaviour of the animals and by collecting data
from them after sacrificing them after seven days.49
Already the general behaviour of the animals showed
obvious diﬀerences. Animals of the control group, where the
infection was not treated locally, were severely impaired, showing
increased neurological symptoms like head tilting and mechanical
head motions as well as elevated body temperature. In contrast,
animals of the study group barely showed any disorders of their
general condition. When the middle ear was irrigated after the end
of the experiment, P. aeruginosa bacteria were detected in high
concentrations in every middle ear of the control group, but were
almost completely eliminated in the study group. The examination
of diﬀerent organs revealed that the infection had spread through-
out the body in the control group, whereas a bacterial spread was
Fig. 14 Scheme of the histological results from animal experiments carried out
subcutaneously in rabbits. A: part of a Bioverits II implant coated with
mesoporous silica; A+: part of a Bioverits II implant coated with mesoporous
silica, modified with an aminosilane and loaded with BMP2; B: cell-rich layer of
connecting tissue near to the implant; C: surrounding tissue. The layer of
connective tissue is considerably thicker on the side where BMP2 is present,
proving the local action of the growth factor.31,34 Note the shape of the
borderline between B and C which is indicative of a diﬀusive action of the
BMP2. Therefore, it can be assumed that BMP2 does not act directly from
the implant surface, but becomes detached (possibly also by dissolution of the
mesoporous silica coating).
Chem Soc Rev Tutorial Review
Pu
bl
ish
ed
 o
n 
25
 M
ar
ch
 2
01
3.
 D
ow
nl
oa
de
d 
by
 T
ec
hn
isc
he
 In
fo
rm
at
io
ns
bi
bl
io
th
ek
 (T
IB
) o
n 2
6/1
0/2
01
7 0
9:1
9:3
2. 
View Article Online
3858 Chem. Soc. Rev., 2013, 42, 3847--3861 This journal is c The Royal Society of Chemistry 2013
prevented in the study group. All the middle ears in the control
group showed an abscess, whereas only one of the seven animals
in the study group showed this symptom (Fig. 19).49
This animal experiment clearly proved the eﬃcacy of the
implant-supported local drug delivery system which we have
developed in the course of our work. It is especially noteworthy
that the estimated total released amount of ciprofloxacin is
extremely small, namely only ca. 1.44 mg (with a calculated surface
of the prosthesis of 0.16 cm2 and the total release amount of
9 mg of ciprofloxacin per cm2 of the macroscopic surface) and
Fig. 15 Scheme showing the construction of the diﬀerent materials used in this study. Diﬀerent modifications were carried out to achieve a high loading and a controlled
release of ciprofloxacin frommesoporous silica films. Glass substrates were functionalized successively with a mesoporous silica film (sample A), by the introduction of sulfonic
acid groups (sample B), by loading with ciprofloxacin (sample C), by the application of a surface layer derived from bis(trimethoxysilyl)hexane by dip-coating (sample D), and
by the additional application of a surface layer derived from dioctyltetramethyldisilazane by evaporation-coating (sample E). Adapted with permission from ref. 32.
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would have practically no eﬀect when applied systemically. The
local application of such a small amount, however, can eﬀec-
tively curb a bacterial infection in the middle ear. The middle
ear is an especially favourable place for the application of such
a local drug delivery device, as by its anatomy, it is concluded
and there is no through flow of body fluids.
Outlook: mesoporous silica nanoparticles as
drug carriers in the middle ear
Apart from bacterial middle ear infections, cholesteatomas are
another disease of the middle ear, consisting of a destructive
and expanding growth of epithelial cells in the middle ear.
Cholesteatomas often have the harmful property to arise
again after surgical removal. To prevent this relapse, our next
aim is to establish a local drug delivery system for retinoic
acid in the middle ear. Retinoic acid is an antiproliferativum
(a growth-inhibiting agent) and has been shown to counter the
formation of cholesteatoma relapses in animal experiments
on guinea pigs.50 In addition, the nowadays common practice
to use collagen pads as interponates to soften the transition
between the tympanic membrane and the head part of the
prosthesis (Fig. 1b) seems to be in need of improvement in
our view. Therefore, we aim to develop a composite pad of
silicone and mesoporous silica nanoparticles (Fig. 1d) where
the viscoelastic properties of the silicone can be adapted to
guarantee optimal sound transmission. The silica nanoparticles
shall be loaded with retinoic acid to prevent the relapse of a
cholesteatoma.
Fig. 16 Ciprofloxacin (CFX) release profiles conducted in 0.01 M PBS of drug
delivery systems based on glass substrates (filled marks) and Bioverits II sub-
strates (unfilled marks), and of native Bioverits II (cross marks). The drug delivery
systems are described in Fig. 15. A + CFX (squares): mesoporous silica coating
loaded with CFX; C (circles): sulfonate-modified mesoporous silica coating loaded
with CFX; D, triangles: as C, with an additional polymeric layer derived from
bis(trimethoxysilyl)hexane; E (stars): as D, with an additional hydrophobizing layer
derived from tetramethyldioctyldisilazane. Adapted with permission from ref. 32.
Fig. 17 Results of biocompatibility tests of drug release samples based on glass
slides as a support.32 NIH3T3 fibroblast cells cultured under standard cell culture
conditions at 37 1C for 72 h. Cell densities are given in respect to the density of
cells which had grown on standard cell culture plastic (CCP); this value was set to
1. B: sulfonate-modified mesoporous silica coating; C: sulfonate-modified meso-
porous silica coating loaded with CFX; D: as C, with an additional polymeric layer
derived from bis(trimethoxysilyl)hexane; E: as D, with an additional hydro-
phobizing layer derived from tetramethyldioctyldisilazane. Adapted with permis-
sion from ref. 32.
Fig. 18 Antibacterial eﬃcacy of a ciprofloxacin-loaded mesoporous silica film
against P. aeruginosa bacteria (luminescent PAO1 CTX::lux) after 6 h in vitro. A:
mesoporous silica film on a glass substrate; B: as A, but with sulfonic acid
modification; C: as B, but loaded with ciprofloxacin. A plain glass sample (glass)
is used as a reference; radiance is given relative to the value of this sample which
was set to 1. Reprinted with permission from ref. 32.
Fig. 19 Results from animal studies in intentionally infected middle ears of
rabbits. Left: infected tissues and an abscess as observed in all the middle ears of
the animals of the control group, but in only one of the animals in the
study group; right: healthy situation as observed in most of the animals of the
study group.
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Conclusions
In this tutorial review we present our scientific results obtained
during the construction of functional middle ear prostheses based
onmesoporous silica layers. Additionally, we describe step-by-step
the path from chemical synthesis and physicochemical characteri-
zation via in vitro testing in cell cultures to in vivo animal
experiments. Already at the start, when planning the chemical
synthesis, problems with biocompatibility should be kept in
mind. An elaborate physico-chemical characterization allows for
the interpretation of further results obtained. In vitro cell culture
experiments provide a first test for biocompatibility. Care must be
taken in this step, as there are diﬀerent types of test conditions
and cells which have variable sensitivity to their surrounding
(i.e. a biomaterials surface). In vitro tests may also provide first
clues about the eﬃcacy of an implant with a specific function; an
example is the testing of antibacterial biomaterials in bacterial
cell cultures. Finally, animal studies allow us to evaluate the
function of an implant and its interactions with the surrounding
living tissue. It has to be noted that this development from
chemical synthesis to the application in a living body is only
possible through a close interdisciplinary collaboration between
chemists and biochemists, biologists and surgeons, requiring
cooperativeness and the willingness to learn the specific scientific
‘‘languages’’ of the other disciplines.
The use of a mesoporous silica coating on a prosthesis, as
described in this review, appears to us as an especially favourable
medicinal or pharmaceutical form to use this novel and interesting
biomaterial. Our work has shown that sensitive biomolecules like
growth factors can be attached to such coatings spatioselectively
(i.e. only on a certain part of an implant) and that the pore system
can be used for a local drug delivery system. The results obtained
should be easily transferable to other types of prostheses and
implants, as long as these support the preparation of a meso-
porous silica film on their surface.
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